ArticleACS nano2013
Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood.
Article in ACS nano, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- Selective capture and digital counting of intact HIV pseudovirus using designer DNA nets, tethered motion, and photonic resonator interferometric scattering microscopy.APL bioengineering · 2026Article
- Spatiotemporal Confinements of Distance-Dependent Emitters for Enhancing Plasmonic Signals.ACS applied materials & interfaces · 2026Article
- Spatial Designs on Metamaterial Sensors for Enhancing Signals and Detecting Extracellular Vesicles.ACS applied materials & interfaces · 2025Article
- A luminescence-based point-of-care HIV viral load test for antiretroviral therapy monitoring.Lab on a chip · 2025Article
- Ultraprecise Detection of Influenza Virus by Antibody-Modified Graphene Transistors.Sensors (Basel, Switzerland) · 2025Article
- Plasmon-enhanced fluorescence for biophotonics and bio-analytical applications.Frontiers in chemistry · 2024Review
- Aptamer-Based Point-of-Care Devices: Emerging Technologies and Integration of Computational Methods.Biosensors · 2023Review
- Recent development of surface-enhanced Raman scattering for biosensing.Journal of nanobiotechnology · 2023Review
- Review of HIV Self Testing Technologies and Promising Approaches for the Next Generation.Biosensors · 2023Review
- Advancements in Testing Strategies for COVID-19.Biosensors · 2022Review
- Plasmonic Biosensors: Review.Biology · 2022Review
- Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination.Biosensors & bioelectronics · 2022Article
- The Role of Ligand Rebinding and Facilitated Dissociation on the Characterization of Dissociation Rates by Surface Plasmon Resonance (SPR) and Benchmarking Performance Metrics.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Micro and Nanoscale Technologies for Diagnosis of Viral Infections.Small (Weinheim an der Bergstrasse, Germany) · 2021Review
- Recent Advancements in Biosensing Approaches for Screening and Diagnostic Applications.Current opinion in biomedical engineering · 2021Article
- A review on plasmonic and metamaterial based biosensing platforms for virus detection.Sensing and Bio-Sensing Research · 2021Review
- Plasmonic Nanotweezers and Nanosensors for Point-of-Care Applications.Advanced optical materials · 2021Article
- Article
- A comprehensive review on plasmonic-based biosensors used in viral diagnostics.Communications biology · 2021Review
- Current progress on COVID-19 related to biosensing technologies: New opportunity for detection and monitoring of viruses.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2021Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Infectious diseases such as HIV and hepatitis B pose an omnipresent threat to global health. Reliable, fast, accurate, and sensitive platforms that can be deployed at the point-of-care (POC) in multiple settings, such as airports and offices, for detection of infectious pathogens are essential for the management of epidemics and possible biological attacks. To the best of our knowledge, no viral load technology adaptable to the POC settings exists today due to critical technical and biological challenges. Here, we present for the first time a broadly applicable technology for quantitative, nanoplasmonic-based intact virus detection at clinically relevant concentrations. The sensing platform is based on unique nanoplasmonic properties of nanoparticles utilizing immobilized antibodies to selectively capture rapidly evolving viral subtypes. We demonstrate the capture, detection, and quantification of multiple HIV subtypes (A, B, C, D, E, G, and subtype panel) with high repeatability, sensitivity, and specificity down to 98 ± 39 copies/mL (i.e., HIV subtype D) using spiked whole blood samples and clinical discarded HIV-infected patient whole blood samples validated by the gold standard, i.e., RT-qPCR. This platform technology offers an assay time of 1 h and 10 min (1 h for capture, 10 min for detection and data analysis). The presented platform is also able to capture intact viruses at high efficiency using immuno-surface chemistry approaches directly from whole blood samples without any sample preprocessing steps such as spin-down or sorting. Evidence is presented showing the system to be accurate, repeatable, and reliable. Additionally, the presented platform technology can be broadly adapted to detect other pathogens having reasonably well-described biomarkers by adapting the surface chemistry. Thus, this broadly applicable detection platform holds great promise to be implemented at POC settings, hospitals, and primary care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.